Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Royal Brompton Hospital · Imperial College London · +15 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
625
total citations
- FWCI
- 57.31
- Percentile
- 100%
- References
- 22
Citations per year
Authors
11- TMToby M. MaherCorresponding
Royal Brompton Hospital, Imperial College London, National Institute for Health Research
- TJTamera J. Corte
Royal Prince Alfred Hospital, University of Sydney
- AFAryeh Fischer
Bristol-Myers Squibb (United States), University of Colorado Denver
- MKMichael Kreuter
Heidelberg University
- DJDavid J. Lederer
Columbia University Irving Medical Center, Regeneron (United States)
Topics & keywords
Topics
Keywords
- Medicine
- Pirfenidone
- DLCO
- Spirometry
- Interstitial lung disease
- Diffusing capacity
- Vital capacity
- Placebo
No related works found for this paper.